British drugmaker GSK said on Tuesday its experimental therapy, linerixibat, met its main goal in a late-stage trial to treat ...

GSK has reported promising results with a drug to treat the severe itching that plagues patients with rare cholestatic liver ...

Tharimmune, Inc. (NASDAQ:THAR) shares initially traded higher on Monday, but have since reversed after the company presented ...

Data presented at The Liver Meeting include adverse events as well as an assessment of patients’ relief of pruritus symptom scores when correlated to pharmacokinetics of TH104. Patients with ...

Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024PARIS, FRANCE, 18 ...

Cirrhosis is a progressive liver condition that often remains hidden in its early stages. The disease, marked by irreversible ...

On Friday, Gilead Sciences, Inc. (NASDAQ:GILD) revealed data from a two-and-a-half-year interim analysis from the ongoing ...

Journalist Annie Lowrey has a rare disease that causes a near-constant itch that doesn't respond to most treatments. She ...

Results showed a significantly higher prevalence of liver disease among patients with chronic pruritus compared to healthy controls. Patients with liver diseases of different etiologies, including ...

The molecule's dual mechanism of action targets both the µ-opioid and kappa-opioid receptors and may inhibit IL-17 inflammatory cytokine expression, which is implicated in the body's itch circuitry.

Shares of Tharimmune Inc. shot up more than 100% in early trading Oct. 30 as the firm disclosed regulatory backing to launch a phase II trial this quarter testing TH-104, a transdermal buccal film ...